The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Interferons and Their Stimulated Genes in the Tumor Microenvironment
Open accessAbstract
Constitutive expression of interferons (IFNs) and activation of their signaling pathways have pivotal roles in host responses to malignant cells in the tumor microenvironment. IFNs are induced from the innate immune system and in tumors through stimulation of Toll-like receptors (TLRs) and through other signaling pathways in response to specific cytokines. Although in the oncologic context IFNs have been thought of more as exogenous pharmaceuticals, the autocrine and paracrine actions of endogenous IFNs probably have even more critical effects on neoplastic disease outcomes. Through high-affinity cell surface receptors, IFNs modulate transcriptional signaling, leading to regulation of over 2000 genes with varying patterns of temporal expression. Induction of the gene products by both unphosphorylated and phosphorylated STAT1 after ligand binding, results in alterations in tumor cell survival, inhibition of angiogenesis, and augmentation of actions of T, natural killer (NK), and dendritic cells. The interferon-stimulated gene (ISG) signature can be a favorable biomarker of immune response but, in a seemingly paradoxical finding, a specific subset of the full ISG signature indicates an unfavorable response to DNA damaging interventions such as radiation. IFNs in the tumor microenvironment thus can alter the emergence, progression, and regression of malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–221 of 221
Wang, T., Huang, C., López-Coral, A., Slentz‐Kesler, K., Xiao, M., Wherry, E. J., & Kaufman, R. E. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1011498 · Cited by 50
Emerging Roles for Immunomodulatory Functions of Free ISG15
Campbell, J. A., & Lenschow, D. J. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0064 · Cited by 44
Identification of Interferon-β-Stimulated Genes that Inhibit Angiogenesis In Vitro
Taylor, K. L., Leaman, D. W., Grane, R., Mechti, N., Borden, E. C., & Lindner, D. J. (2008) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0030 · Cited by 43
Self-citationNakaji, M., Yano, Y., Ninomiya, T., Seo, Y., Hamano, K., Yoon, S., Kasuga, M., Teramoto, T., Hayashi, Y., & Yokozaki, H. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh028 · Cited by 43
Badgwell, B. D., Lesinski, G. B., MAGRO, C. M. J., Abood, G. J., Skaf, A., & Carson, W. E. (2004) · Journal of Surgical Research · doi:10.1016/j.jss.2003.09.005 · Cited by 35
Kim, D. H. (., Kong, J. H., Byeun, J. Y., Jung, C. W., Xu, W., Liu, X., Kamel‐Reid, S., Kim, Y.-K., Kim, H., & Lipton, J. H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1638 · Cited by 35
STAT1 represses hypoxia-inducible factor-1-mediated transcription
Hiroi, M., Mori, K., Sakaeda, Y., Shimada, J., & Ohmori, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.138 · Cited by 33
Normal human epidermis contains an interferon-like protein.
Yaar, M., Palleroni, A. V., & Gilchrest, B. A. (1986) · The Journal of Cell Biology · doi:10.1083/jcb.103.4.1349 · Cited by 33
Lüth, S., Schrader, J., Zander, S., Carambia, A., Buchkremer, J., Huber, S., Reifenberg, K., Yamamura, K., Schirmacher, P., Lohse, A. W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3232 · Cited by 33
Usp18 Promotes Conventional CD11b+ Dendritic Cell Development
Cong, X.-L., Lo, M., Reuter, B., Yan, M., Fan, J.-B., & Zhang, D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101609 · Cited by 29
Starr, R., Fuchsberger, M., Lau, L., Uldrich, A., Goradia, A., Willson, T., Verhagen, A., Alexander, W., & Smyth, M. (2009) · Journal of Immunology · doi:10.4049/jimmunol.0901010 · Cited by 28
Kumar, K. G., Liu, J., Li, Y., Yu, D., Thomas‐Tikhonenko, A., Herlyn, M., & Fuchs, S. Y. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.9.4569 · Cited by 27
Schiller, J. H., Storer, B. E., Paulnock, D. M., Brown, R. R., Datta, S. P., Witt, P. L., & Borden, E. C. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114827 · Cited by 26
Self-citationHage, F. E., Durgeau, A., & Mami‐Chouaib, F. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06777.x · Cited by 24
Reznikov, L. L., Puren, A. J., Fantuzzi, G., Mühl, H., Shapiro, L., Yoon, D., Cutler, D. L., & Dinarello, C. A. (1998) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1998.18.897 · Cited by 24
Arakura, F., Hida, S., Ichikawa, E., Yajima, C., Nakajima, S., Saida, T., & Taki, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3249 · Cited by 24
Interferon system defects in malignant T-cells.
Heyman, M. M., Grandér, D., Brøndum‐Nielsen, K., CEDERBLAD, B., Liu, Y., Xu, B., & Einhorn, S. (1994) · PubMed · Cited by 23
Is interferon produced in physiologic conditions?
Bocci, V. A. (1980) · Medical Hypotheses · doi:10.1016/0306-9877(80)90091-2 · Cited by 20
Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2
Win-Piazza, H., Schneeberger, V. E., Chen, L., Pernazza, D., Lawrence, H. R., Sebti, S. M., Lawrence, N. J., & Wu, J. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.034 · Cited by 20
How virus persistence can initiate the tumorigenesis process
Avanzi, S. (2013) · World Journal of Virology · doi:10.5501/wjv.v2.i2.102 · Cited by 18
Borden, E. C., Sidky, Y. A., Ertürk, E., Wierenga, W., & Bryan, G. T. (1990) · PubMed · Cited by 17
Self-citation
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
Yang, R., Sun, L., Li, C.-F., Wang, Y.-H., Yao, J., Li, H., Yan, M., Chang, W.-C., Hsu, J.-M., Cha, J.-H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21099-2 · Cited by 632
Metadata
- Authors
- Cheon, H., Borden, E. C., & Stark, G. R.
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 41
- Issue
- 2
- Pages
- 156-173
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W2128402485
- Cited by
- 255
- References
- 221
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.